BOSTON – OPTIMAL LEFT MAIN TRIAL – Rationale, Design, and Latest Status
EBC 2020 - LIVE! BOSTON SCIENTIFIC – Sponsored Symposium: OPTIMAL LEFT MAIN TRIAL - Rationale, Design, and Latest Status.
EBC 2020 - LIVE! BOSTON SCIENTIFIC – Sponsored Symposium: OPTIMAL LEFT MAIN TRIAL - Rationale, Design, and Latest Status.
EBC 2020 - LIVE! IMAGING SESSION: NOBLE IVUS and a glimpse into OCTOBER - Dr Niels Ramsing Holm
EBC 2020 - LIVE!LEFT MAIN SESSION:Is intracoronary imaging mandatory? Data from Noble and Excel - Dr José De La TorreDOWNLOAD PDF
EBC 2020 - LIVE! NEWS SESSION: A glimpse into the EBC-MAIN study - Dr David Hildick-Smith DOWNLOAD PDF
EBC 2020 - LIVE!NEWS SESSION:A glimpse into the POLBOS LM study - Pr Robert GilDOWNLOAD PDF
EBC 2020 - LIVE! NEWS SESSION: The DEFINITION II Trial - Dr Shao-Liang Chen
European Bifurcation Club 2019, EBC 2019 - Barcelona, Spain LM SESSION Ideal LM Author: Rober Jan Van Geuns, MD, PhD, Radboudumc, The Netherlands CONCLUSIONS After 2 years, in patients undergoing LM-PCI, a Bioabsorbable Polymer Everolimus-Eluting Platinum Chromium stent (Synergy) followed by 4 months DAPT was non-inferior to a Permanent Polymer Everolimus- Eluting Cobalt Chromium stent (Xience) followed by 12 months DAPT with respect to the composite end point of death from any cause or MI or ischemia-driven target vessel revascularization. No difference in ischemic events up to 24 months • No difference in definite/probable stent thrombosis • No stent thrombosis in either group from 4 to 12 months (Synergy off DAPT) Excess BARC 3 or 5 bleeding in short DAPT group but... •4/11 were on OAC/NOAC (2 on triple Rx) and 7/11 were off DAPT • Trial not powered for bleeding events
European Bifurcation Club 2019, EBC 2019 - Barcelona, Spain NEWS 3 The Twilight Trial: Ticagrelor with or without aspirin in high-risk patients after PCI Author: Vladimir Dzavik, MD, PhD, Toronto General Hospital, Canada TRIAL HYPOTHESIS In patients undergoing PCI who are at high risk for ischemic or hemorrhagic complications and who have completed a 3-month course of dual antiplatelet therapy with ticagrelor plus aspirin, continued treatment with ticagrelor monotherapy would be superior to ticagrelor plus aspirin with respect to clinically relevant bleeding and would not lead to ischemic harm. TRIAL OBJECTIVES Primary Objective: To determine the impact of SAPT (ticagrelor monotherapy) versus DAPT (ticagrelor plus aspirin) for 12 months in reducing clinically relevant bleeding (BARC 2, 3 or 5) among high-risk patients who have undergone successful PCI. Secondary Objective: To determine the impact of SAPT (ticagrelor monotherapy) versus DAPT (ticagrelor plus aspirin) for 12 months on major ischemic adverse events (all-cause death, non-fatal MI or stroke) among high-risk patients who have undergone successful PCI. CONCLUSION In high-risk patients who underwent PCI and were treated with ticagrelor and aspirin for 3 months without any major adverse (bleeding or ischemic) events, an antiplatelet strategy of continuing ticagrelor monotherapy resulted in: substantially less bleeding than ticagrelor plus aspirin without increasing ischemic events over a period of 1 year